MaxCyte, Inc. (LON:MXCT - Get Free Report)'s stock price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 346 ($4.43) and traded as low as GBX 264 ($3.38). MaxCyte shares last traded at GBX 264 ($3.38), with a volume of 29,582 shares.
MaxCyte Price Performance
The company has a 50 day moving average price of GBX 342.21 and a 200-day moving average price of GBX 313.08. The company has a market cap of £354.69 million, a price-to-earnings ratio of -9.85 and a beta of 1.13. The company has a quick ratio of 14.38, a current ratio of 9.81 and a debt-to-equity ratio of 8.59.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
